Skip to main content

Table 1 Baseline characteristics of participants

From: Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Variable

Arylia (N = 95)

Prolia® (N = 95)

Age, year

61.59 (5.94)

60.60 (6.62)

Height, cm

153.14 (5.88)

154.59 (5.74)

Weight, kg

66.44 (11.28)

64.72 (9.88)

Body-mass index, kg/m2

28.35 (4.69)

27.10 (4.09)

T score, SD

 Spine (L1–L4)

 − 3.09 (0.54)

 − 3.10 (0.54)

 Total hip

 − 1.27 (0.83)

 − 1.29 (0.87)

 Femoral neck

 − 1.84 (0.83)

 − 1.88 (0.68)

25 (OH) vitamin D3, ng/mL

41.80 (19.48)

46.53 (22.15)

Albumin-adjusted serum calcium, mg/dL

9.15 (0.55)

9.10 (0.53)

Previous bisphosphonate use

6

2

  1. Data are mean (SD)